What is the Life Expectancy for Myotonic Dystrophy?
At a Glance
Myotonic dystrophy can reduce life expectancy, but the impact varies widely between Type 1 and Type 2. While classic adult-onset Type 1 has an average lifespan around 58 years, proactive heart and lung care can significantly improve both the length and quality of your life.
In this answer
3 sections
Yes, myotonic dystrophy typically reduces overall life expectancy, but the impact varies dramatically [1]. How much it affects your lifespan depends heavily on the specific type you have (Type 1 or Type 2), the age your symptoms first appeared, and how proactively your care is managed [2][3].
Because the leading causes of shortened lifespan in myotonic dystrophy are related to the heart and lungs, early detection and treatment of these specific issues can significantly improve both the length and quality of your life [4][5]. Many lifespan statistics are based on historical data, and modern medical guidelines emphasizing proactive heart and lung care aim to significantly improve these outcomes [6][3].
How Life Expectancy Differs by Type
Myotonic dystrophy is divided into Type 1 (DM1) and Type 2 (DM2). The disease behaves differently in everyone, but research provides general timelines based on these diagnoses.
Myotonic Dystrophy Type 1 (DM1)
DM1 is generally the more severe form of the condition. Life expectancy is closely tied to when the symptoms first begin, which is related to the size of the genetic mutation, known as a CTG repeat expansion [2][7]. You can usually find your specific “repeat length” or “repeat number” on your genetic testing report to help you and your doctor understand your individual risks.
- Adult-Onset (Classic) DM1: This is the most common form, with symptoms typically beginning in the 20s or 30s. Research indicates that the historical average age of death for someone with classic adult-onset DM1 is around 58 years old [1][8]. Overall, the mortality risk is roughly six times higher than that of the general population [1].
- Congenital and Childhood-Onset DM1: When symptoms are present at birth (congenital) or begin in early childhood, the disease is more severe [9][10]. Congenital DM1 carries a high risk of infant mortality, and for those who survive, life expectancy is notably shortened, with some passing away in their 30s or 40s [2][8].
Myotonic Dystrophy Type 2 (DM2)
DM2 is generally a milder condition with a more unpredictable set of symptoms than DM1 [11][3]. While studies show that life expectancy is reduced compared to the general public, people with DM2 often live significantly longer than those with DM1 [12]. There is no single average age of death established for DM2 because the disease progression is highly variable from person to person [12].
What Are the Primary Risks to Life?
For both DM1 and DM2, muscle weakness isn’t just a problem for your arms and legs—it also affects the internal muscles that keep you alive. The vast majority of premature passing in myotonic dystrophy is caused by complications in these areas:
- The Heart (Cardiac Issues): The disease can damage the electrical system of the heart. This leads to arrhythmias (irregular heartbeats) and conduction defects (blocks in the heart’s electrical signals), which can cause sudden cardiac death [4][13][14].
- The Lungs (Respiratory Issues): Weakness in the diaphragm and swallowing muscles makes breathing difficult, especially at night. It also increases the risk of inhaling food or liquid into the lungs, leading to pneumonia [5][15]. Respiratory failure is a leading cause of mortality, particularly for people with DM1 [15][16].
- Severe Infections and Cancer: People with both DM1 and DM2 face an elevated risk of certain cancers. However, malignancies and severe respiratory infections (like pneumonia) are particularly notable as leading causes of mortality for people living with DM2 [12][17].
Adding Years to Your Life: The Power of Proactive Care
While there is currently no cure for myotonic dystrophy, how you manage the disease plays a critical role in your survival [3][18]. You and your care team can take specific, highly effective actions to protect your lifespan [5][6].
- Protecting the Heart: Annual cardiac screenings, including an EKG (electrocardiogram), are vital [4][19]. If doctors detect dangerous heart rhythms early, they can implant a device to protect you. A pacemaker is used to treat dangerously slow rhythms or electrical blocks, while an ICD (implantable cardioverter-defibrillator) can shock the heart out of dangerously fast, life-threatening rhythms. These devices are proven lifesavers that prevent sudden cardiac death [4][20].
- Protecting the Lungs: Regular breathing tests and sleep studies are crucial for catching nocturnal hypoventilation (shallow breathing at night) [21]. The use of Non-Invasive Ventilation (NIV), such as a BiPAP machine while you sleep, dramatically improves oxygen levels and prevents respiratory failure [21]. Additionally, your doctor may prescribe a Cough Assist device to help clear your lungs and prevent pneumonia. Consistent use of your prescribed breathing equipment is one of the most important things you can do to protect your lifespan [15][16].
- Surgical and Anesthesia Safety: People with myotonic dystrophy are at an unusually high risk for severe, life-threatening complications when given general anesthesia or heavy sedatives [6]. You can completely avoid this preventable risk by ensuring your anesthesiologist and surgical team know you have myotonic dystrophy well before any procedure.
By assembling a multidisciplinary care team—including a neurologist, cardiologist, and pulmonologist—you can actively monitor for these preventable complications and protect your health for as long as possible [6][22].
Common questions in this guide
What is the average life expectancy for myotonic dystrophy type 1?
Does myotonic dystrophy type 2 shorten your lifespan?
What are the primary causes of death in myotonic dystrophy?
Can treatment improve life expectancy for myotonic dystrophy?
Why is anesthesia dangerous if you have myotonic dystrophy?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my genetic testing report, what is my specific CTG repeat length, and how does that impact my risk profile?
- 2.How often should I be getting baseline cardiac evaluations, such as an EKG or Holter monitor?
- 3.Can you refer me to a pulmonologist to arrange a sleep study to check for nocturnal hypoventilation?
- 4.What specific precautions do we need to document in my medical chart regarding anesthesia and sedatives?
- 5.At what point should we consider interventions like a pacemaker, ICD, or BiPAP machine for my specific case?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (22)
- 1
Multiorgan Involvement and Mortality in Individuals With Adult-Onset Myotonic Dystrophy (DM1)-A Danish Register-Based Study I.
Werlauff U, Rudolfsen JH, Andersen H, et al.
European journal of neurology 2025; (32(4)):e70135 doi:10.1111/ene.70135.
PMID: 40195688 - 2
Molecular genetics of congenital myotonic dystrophy.
Lanni S, Pearson CE
Neurobiology of disease 2019; (132()):104533 doi:10.1016/j.nbd.2019.104533.
PMID: 31326502 - 3
Myotonic dystrophy type 2: the 2020 update.
Meola G
Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2020; (39(4)):222-234 doi:10.36185/2532-1900-026.
PMID: 33458578 - 4
Cardiovascular manifestations of myotonic dystrophy.
Wahbi K, Furling D
Trends in cardiovascular medicine 2020; (30(4)):232-238 doi:10.1016/j.tcm.2019.06.001.
PMID: 31213350 - 5
Cardiac Involvement and Arrhythmias Associated with Myotonic Dystrophy.
McBride D, Deshmukh A, Shore S, et al.
Reviews in cardiovascular medicine 2022; (23(4)) doi:10.31083/j.rcm2304126.
PMID: 36177340 - 6
Myotonic dystrophy type 1: palliative care guidelines.
Willis D, Willis T, Bassie C, et al.
BMJ supportive & palliative care 2024; doi:10.1136/spcare-2023-004748.
PMID: 38253488 - 7
Association Between Mutation Size and Cardiac Involvement in Myotonic Dystrophy Type 1: An Analysis of the DM1-Heart Registry.
Chong-Nguyen C, Wahbi K, Algalarrondo V, et al.
Circulation. Cardiovascular genetics 2017; (10(3)) doi:10.1161/CIRCGENETICS.116.001526.
PMID: 28611030 - 8
Survival in myotonic dystrophy type 1: a long time follow up-study with special reference to gastrointestinal symptoms.
Rönnblom A, Ekbom A
Upsala journal of medical sciences 2024; (129()) doi:10.48101/ujms.v129.10663.
PMID: 39376588 - 9
Clinical and genetic characteristics of childhood-onset myotonic dystrophy.
Stokes M, Varughese N, Iannaccone S, Castro D
Muscle & nerve 2019; (60(6)):732-738 doi:10.1002/mus.26716.
PMID: 31520483 - 10
Childhood-onset form of myotonic dystrophy type 1 and autism spectrum disorder: Is there comorbidity?
Angeard N, Huerta E, Jacquette A, et al.
Neuromuscular disorders : NMD 2018; (28(3)):216-221 doi:10.1016/j.nmd.2017.12.006.
PMID: 29361396 - 11
Comparative Sleep Disturbances in Myotonic Dystrophy Types 1 and 2.
Romigi A, Franco V, Placidi F, et al.
Current neurology and neuroscience reports 2018; (18(12)):102 doi:10.1007/s11910-018-0903-x.
PMID: 30382420 - 12
Life expectancy and causes of death in patients with Myotonic Dystrophy Type 2.
Damen MJ, Muilwijk OG, Olde Dubbelink TB, et al.
Journal of neuromuscular diseases 2024; (11(6)):1221-1228 doi:10.3233/JND-240089.
PMID: 39240646 - 13
Cardiac Pathology in Myotonic Dystrophy Type 1.
Mahadevan MS, Yadava RS, Mandal M
International journal of molecular sciences 2021; (22(21)) doi:10.3390/ijms222111874.
PMID: 34769305 - 14
Clinical Care Recommendations for Cardiologists Treating Adults With Myotonic Dystrophy.
McNally EM, Mann DL, Pinto Y, et al.
Journal of the American Heart Association 2020; (9(4)):e014006 doi:10.1161/JAHA.119.014006.
PMID: 32067592 - 15
Effect and impact of mechanical ventilation in myotonic dystrophy type 1: a prospective cohort study.
Boussaïd G, Prigent H, Laforet P, et al.
Thorax 2018; (73(11)):1075-1078 doi:10.1136/thoraxjnl-2017-210610.
PMID: 29572271 - 16
A patient with myotonic dystrophy diagnosed after experiencing sudden respiratory failure: a case report.
Nishihara N, Tachibana S, Sonoda H, Yamakage M
JA clinical reports 2020; (6(1)):80 doi:10.1186/s40981-020-00388-7.
PMID: 33033872 - 17
A novel discovery of elevated risk of neuroendocrine tumors in patients with myotonic dystrophy.
Hameed B, Ahmadzada M, McNeel TS, et al.
Journal of the neurological sciences 2025; (478()):123722 doi:10.1016/j.jns.2025.123722.
PMID: 41100969 - 18
Update on the clinical and therapeutic aspects of myotonic dystrophy type 1.
Takahashi MP
Current opinion in neurology 2025; (38(5)):531-537 doi:10.1097/WCO.0000000000001374.
PMID: 40377703 - 19
Comprehensive Cardiovascular Management of Myotonic Dystrophy Type 1 Patients: A Report from the Italian Neuro-Cardiology Network.
Russo V, Antonini G, Massa R, et al.
Journal of cardiovascular development and disease 2024; (11(2)) doi:10.3390/jcdd11020063.
PMID: 38392277 - 20
Risk for Complications after Pacemaker or Cardioverter Defibrillator Implantations in Patients with Myotonic Dystrophy Type 1.
Sochala M, Wahbi K, Sorbets E, et al.
Journal of neuromuscular diseases 2017; (4(3)):175-181 doi:10.3233/JND-170232.
PMID: 28598855 - 21
Sleep-disordered breathing and effects of non-invasive ventilation on objective sleep and nocturnal respiration in patients with myotonic dystrophy type I.
Spiesshoefer J, Runte M, Heidbreder A, et al.
Neuromuscular disorders : NMD 2019; (29(4)):302-309 doi:10.1016/j.nmd.2019.02.006.
PMID: 30898523 - 22
Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert's disease.
Gutiérrez Gutiérrez G, Díaz-Manera J, Almendrote M, et al.
Medicina clinica 2019; (153(2)):82.e1-82.e17 doi:10.1016/j.medcli.2018.10.028.
PMID: 30685181
This page provides educational information about life expectancy and disease management for myotonic dystrophy. It is not a substitute for professional medical advice. Always discuss your specific prognosis and care plan with your neurologist and specialized care team.
Get notified when new evidence is published on Myotonic dystrophy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.